List of Excipients in Branded Drug ASPARLAS

ASPARLAS Excipient Strategy and Commercial Opportunities

Last updated: September 27, 2026

ASPARLAS (calaspargase pegol-mknl) is a PEGylated L-asparaginase enzyme approved for use in acute lymphoblastic leukemia and acute lymphoblastic lymphoma in patients age 1 month and older. Its commercial value comes from reduced dosing frequency compared with native L-asparaginase and a formulation that supports refrigerated liquid storage. The principal excipient opportunities are stability improvement, lower infusion burden, improved pediatric usability, container-closure optimization, and global supply resilience.

ASPARLAS is not a conventional small-molecule generic opportunity. Calaspargase pegol-mknl is a complex biologic with a PEG-protein structure, enzyme activity requirements, immunogenicity considerations, and a formulation that must preserve potency during refrigerated storage and dilution. Follow-on entrants would face analytical, clinical, regulatory, and manufacturing barriers.

What is ASPARLAS and how is it formulated?

ASPARLAS contains calaspargase pegol-mknl, a PEGylated recombinant L-asparaginase. The product is administered by intravenous infusion and is supplied as a single-dose vial containing 3,750 units per 5 mL, equivalent to 750 units/mL before dilution.[1]

The formulation is an aqueous solution rather than a lyophilized powder. The inactive ingredients identified in the U.S. prescribing information are:

Excipient or formulation component	Likely technical role
Sodium chloride	Isotonicity and ionic-strength control
Sodium phosphate, dibasic	Buffering and pH control
Sodium phosphate, monobasic	Buffering and pH control
Sucrose	Protein stabilizer and bulking agent
Polysorbate 80	Suppression of interfacial adsorption and aggregation
Water for injection	Vehicle

The product is stored refrigerated at 2°C to 8°C, protected from light, and must not be frozen or shaken. The label directs dilution before administration and limits the post-dilution use period.[1]

The excipient system is conventional for a refrigerated protein biologic. Its commercial importance is higher than the ingredient list suggests because calaspargase pegol-mknl must retain:

• L-asparaginase catalytic activity;
• PEG-protein structural integrity;
• acceptable particle levels;
• low aggregation;
• controlled immunogenicity risk;
• compatibility with infusion bags and administration equipment;
• stability during preparation in pediatric oncology settings.

What excipients protect ASPARLAS stability?

The most important formulation functions are buffering, protein stabilization, isotonicity, and surface protection.

Phosphate buffer

The monobasic and dibasic phosphate salts establish a controlled pH environment. L-asparaginase activity and protein conformation are sensitive to pH excursions. A phosphate system also supports batch-to-batch consistency and dilution behavior.

The principal development risk is phosphate concentration. A higher buffer level may improve pH control but can increase ionic stress or affect protein-protein interactions. A lower level may reduce formulation stress but leave the product more vulnerable to pH drift during storage and dilution.

Sucrose

Sucrose is a standard nonreducing stabilizer for protein therapeutics. It can reduce conformational destabilization during refrigerated storage and protect against stress associated with concentration, handling, and dilution.

For ASPARLAS, sucrose also helps support a liquid formulation without relying on a high concentration of amino acids or polyols that could affect viscosity, osmolality, or infusion tolerability.

Polysorbate 80

Polysorbate 80 reduces adsorption to vial, syringe, tubing, and infusion-bag surfaces. It also reduces aggregation caused by agitation and air-liquid interfaces.

The commercial tradeoff is that polysorbate 80 can undergo hydrolysis and oxidation. Degradation products may generate subvisible particles or interact with the protein. A follow-on formulation could pursue lower polysorbate concentration, a different polysorbate grade, or an alternative surfactant such as polysorbate 20 or poloxamer 188. Each change would require comparative stability and immunogenicity assessment.

Sodium chloride

Sodium chloride supports isotonicity and helps control the product's administration characteristics. Excessive ionic strength can increase aggregation or alter protein interactions, while insufficient ionic strength can affect tonicity and infusion tolerability.

What formulation patents could protect ASPARLAS improvements?

The strongest formulation opportunities would likely involve composition, stability, and administration claims rather than simple substitution of one common excipient for another.

Potential claim categories include:

Patent strategy	Commercial relevance	Likely technical hurdle
Reduced-polysorbate formulation	Lower degradation and particle risk	Must preserve surface protection
Alternative surfactant system	Differentiated formulation and supply security	Comparative immunogenicity and compatibility
Extended refrigerated shelf life	Lower inventory loss and broader distribution	Long-term real-time stability
Room-temperature hold time	Easier preparation in hospitals and emerging markets	Demonstration of potency and particle control
Freeze-thaw-tolerant formulation	More resilient logistics	Protein and PEG stability
Lyophilized ASPARLAS	Lower cold-chain exposure	Reconstitution time, cake quality, and activity retention
Ready-to-use diluted presentation	Lower pharmacy labor	Container volume, sterility, and dose flexibility
Low-volume pediatric formulation	Improved administration for small patients	Dose accuracy and infusion tolerability
Container-closure system	Reduced adsorption or extractables	Compatibility with existing administration equipment

A patent on a new excipient combination would need to show a technically meaningful result. Examples include a defined reduction in high-molecular-weight species, lower subvisible particles, longer stability, improved recovery after dilution, or reduced activity loss after agitation.

A claim directed only to replacing polysorbate 80 with another conventional surfactant may face obviousness and enablement challenges unless the formulation produces an unexpected stability or immunogenicity benefit.

What commercial opportunities exist for ASPARLAS excipients?

Longer shelf life

A formulation that extends refrigerated shelf life could reduce waste at hospitals and specialty distributors. ASPARLAS is used in pediatric oncology, where treatment schedules are protocol-driven but patient dosing can change with body-surface area, toxicity, or treatment delays. Longer dating would help institutions manage vial inventory and reduce product disposal.

The highest-value target is a formulation that maintains enzyme activity and low particle levels for materially longer than the current labeled storage period while preserving the current vial and infusion process.

Reduced cold-chain dependence

A controlled room-temperature presentation would expand distribution into markets with less reliable refrigeration. This opportunity has regulatory value because temperature excursions are a practical concern for biologics shipped to regional oncology centers.

A room-temperature claim would require stability data under both controlled and excursion conditions. The formulation would also need to control PEG cleavage, protein aggregation, potency loss, and particle generation.

Lyophilized presentation

A lyophilized version could improve shipping robustness and reduce sensitivity to transient temperature excursions. It could also separate the drug from some liquid-state degradation pathways involving surfactant oxidation or protein-surface interactions.

The disadvantages are significant:

• added manufacturing cost;
• longer preparation time;
• reconstitution errors;
• potential foaming;
• need for a suitable cake structure;
• possible loss of enzyme activity during freezing and drying.

Lyophilization is more commercially attractive if it provides a clear storage or geographic advantage rather than merely duplicating the existing liquid product.

Pediatric dose flexibility

ASPARLAS dosing is based on body-surface area. A fixed 5 mL vial can create overfill and wastage, particularly for smaller children. Commercial opportunities include:

• lower-dose vials;
• concentration-adjusted presentations;
• premeasured hospital pharmacy kits;
• improved withdrawal efficiency;
• formulations compatible with low-dead-volume syringes.

A smaller vial could improve dose economics but may increase manufacturing, packaging, and distribution costs. The best opportunity is likely a platform that reduces wastage without requiring multiple product strengths.

Ready-to-administer systems

A premixed infusion bag or pharmacy-ready presentation could reduce preparation steps and occupational handling. The product would need to remain stable after dilution and compatible with the selected bag material, tubing, filter, and administration set.

This strategy has higher manufacturing complexity but can create value through hospital workflow savings. It could also reduce preparation variability in pediatric oncology units.

Alternative excipient supply

Polysorbate 80 and other biopharmaceutical excipients can create supply, quality, and oxidation risks. A dual-sourced or alternative-surfactant formulation could reduce dependence on a single excipient supplier.

The opportunity is strongest where the alternative formulation has equivalent clinical performance and can be introduced through a manufacturing or regulatory supplement without changing the dosing regimen.

How does ASPARLAS compare with ONCASPAR?

ASPARLAS and ONCASPAR both provide PEGylated asparaginase activity, but they are not interchangeable products without regulatory and clinical support.

Attribute	ASPARLAS	ONCASPAR
Active ingredient	Calaspargase pegol-mknl	Pegaspargase
Therapeutic class	PEGylated L-asparaginase	PEGylated L-asparaginase
Administration	Intravenous infusion	Intravenous or intramuscular administration, depending on labeling and setting
Dosing interval	Protocol-dependent, with extended activity relative to native enzyme	Protocol-dependent
Formulation	Refrigerated aqueous solution	Refrigerated protein biologic formulation
Key formulation challenge	Maintain activity and PEG-protein stability in liquid storage	Maintain activity, stability, and immunogenicity profile
Competitive advantage	Potentially longer enzyme exposure and different dosing schedule	Established use and broad historical adoption
Follow-on risk	Complex biologic comparability	Complex biologic comparability

ASPARLAS competes primarily on treatment protocol fit, dosing frequency, pharmacokinetics, toxicity management, institutional preference, and supply reliability. Excipient changes that improve administration convenience could strengthen ASPARLAS against ONCASPAR without changing the active moiety.

What is the FDA regulatory status of ASPARLAS?

The FDA approved ASPARLAS in January 2018 for use as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia and acute lymphoblastic lymphoma in patients age 1 month and older.[2]

ASPARLAS is regulated as a biologic under the Public Health Service Act. A follow-on product would generally need to use the biosimilar pathway under section 351(k), unless its development strategy relies on a different regulatory route supported by the product and proposed changes.

An excipient-only modification to the reference product would not automatically qualify as a biosimilar. The developer would need to determine whether the product remains highly similar to the reference biologic and whether the formulation change affects clinical performance, immunogenicity, or interchangeability.

A sponsor developing a materially different formulation could pursue a supplemental application or a separate biologic license application, depending on the degree of change and the proposed labeling. FDA would likely focus on:

• comparative analytical characterization;
• enzyme activity;
• PEG conjugation profile;
• aggregates and particles;
• degradation products;
• sterility and endotoxin;
• pharmacokinetics;
• anti-drug and anti-PEG antibodies;
• hypersensitivity and hepatotoxicity;
• dilution and administration compatibility.

When did ASPARLAS lose orphan exclusivity?

ASPARLAS received orphan-drug designation for its approved use. The standard orphan-drug exclusivity period is seven years from approval, subject to statutory conditions and any applicable pediatric exclusivity.[3]

The seven-year period from the January 2018 approval would run into January 2025. Pediatric exclusivity, if granted for a qualifying written request, could extend applicable exclusivity by six months. Orphan exclusivity does not block all competing products; it prevents FDA approval of the same drug for the same disease or condition during the protected period, subject to statutory exceptions.

Patent protection and regulatory exclusivity are separate. Expiration of orphan exclusivity does not establish freedom to launch a competing biologic if valid patents remain in force.

What is the Orange Book status of ASPARLAS?

ASPARLAS is a biologic, so its central patent and exclusivity analysis is not equivalent to a conventional small-molecule product listed through an abbreviated new drug application.

The FDA Orange Book primarily covers approved drug products and patent information submitted under the Hatch-Waxman framework. Biologics approved under the Public Health Service Act are generally analyzed through the biologics patent and exclusivity framework, including the patent information exchange process associated with the Biologics Price Competition and Innovation Act.

A commercial diligence review should distinguish:

• FDA approval and labeling;
• biologic exclusivity;
• patent term;
• pediatric exclusivity;
• manufacturing know-how;
• PEGylation and conjugation technology;
• formulation claims;
• process claims;
• litigation or settlement restrictions.

No reliable commercial conclusion should be based solely on an Orange Book search for ASPARLAS.

What patent and litigation risks affect ASPARLAS competition?

The relevant patent estate may include claims covering:

1. calaspargase pegol-mknl composition;
2. PEG linker architecture;
3. conjugation methods;
4. enzyme production and purification;
5. pharmaceutical compositions;
6. dosing regimens;
7. treatment of leukemia or lymphoma;
8. stability and storage conditions;
9. administration protocols.

Formulation patents may be more commercially important than broad composition claims once regulatory exclusivity ends. A competitor could potentially develop a distinct excipient system while still encountering process, composition, or method-of-use claims.

A Paragraph IV challenge is not the principal pathway for a biologic approved under section 351(a). A biosimilar sponsor instead faces the BPCIA patent-exchange and litigation framework. The commercial outcome depends on whether the sponsor seeks an early launch, negotiates a license, or accepts a delayed-entry settlement.

Publicly available sources do not establish a single confirmed launch date for an ASPARLAS biosimilar or a market-wide settlement that determines generic-style entry. The more relevant competitive question is whether a follow-on developer can reproduce the reference product's PEGylation profile, activity, impurity profile, and immunogenicity performance at acceptable cost.

How strong is the ASPARLAS patent estate?

The estate is potentially strong in technical barriers even when patent breadth is limited. PEGylated asparaginase is difficult to copy because the active product is defined by more than its amino-acid sequence.

Key barriers include:

• heterogeneous PEG conjugation;
• control of free enzyme and unconjugated PEG;
• enzymatic potency;
• aggregation and fragmentation;
• anti-PEG antibody responses;
• lot-to-lot consistency;
• low-temperature storage;
• manufacturing scale;
• pediatric oncology clinical acceptance.

A biosimilar could overcome individual formulation patents by using different excipients. It would still need to establish comparability across the complete product profile. This makes manufacturing know-how and analytical capability important sources of practical exclusivity.

What generic or biosimilar launch scenarios exist?

Scenario	Timing pressure	Commercial effect
No credible follow-on	Low near-term pressure	Maintains premium pricing and institutional control
Formulation-focused competitor	Moderate	Competes on stability, handling, or geography
Biosimilar with limited interchangeability	Moderate to high	Requires physician or protocol-level adoption
Interchangeable biosimilar	High	Greater substitution and contracting pressure
Hospital-compounded alternative	Limited	Unlikely to replicate biologic comparability
New enzyme or PEGylated alternative	Long term	Could compete on toxicity, dosing, or supply

A successful follow-on product would likely enter first through specialty oncology centers and payer-driven contracting. Hospitals may favor a product with lower preparation burden, smaller vial wastage, or more reliable supply even without automatic substitution.

What licensing opportunities exist for ASPARLAS excipients?

The most realistic licensing targets are formulation and delivery technologies rather than generic excipient supply alone.

Potential partners include:

• biopharmaceutical excipient manufacturers;
• protein stabilization technology companies;
• container-closure suppliers;
• specialty oncology distributors;
• contract development and manufacturing organizations;
• PEGylation technology providers;
• hospital pharmacy automation companies.

A licenseable package would be stronger if it included a defined composition, manufacturing process, stability data, and freedom-to-operate analysis. A generic claim that an excipient "improves stability" is unlikely to support a high-value deal without comparative data.

Commercial structures could include an exclusive field-of-use license, regional rights, milestone payments tied to FDA approval, or a co-development agreement with a biologics manufacturer.

What is the revenue exposure and market opportunity?

Servier does not generally report ASPARLAS revenue as a separately detailed public segment in its standard corporate disclosures. Product-level revenue, market share, and profitability therefore require commercial databases, payer data, or company disclosures beyond the FDA label.

The revenue opportunity is concentrated in:

• pediatric and young-adult leukemia protocols;
• hospitals requiring repeated asparaginase dosing;
• markets where cold-chain reliability limits access;
• institutions seeking fewer administration events;
• health systems sensitive to vial wastage;
• regions where ONCASPAR supply or pricing is unfavorable.

The commercial ceiling is constrained by the size of the acute lymphoblastic leukemia population, protocol-driven use, toxicity-related treatment interruptions, and competition from other asparaginase products.

Key Takeaways

• ASPARLAS uses a conventional protein-biologic excipient system consisting of phosphate salts, sodium chloride, sucrose, polysorbate 80, and water for injection.
• The highest-value formulation opportunities are longer shelf life, room-temperature stability, reduced vial wastage, alternative surfactants, and pharmacy-ready presentations.
• Calaspargase pegol-mknl is a complex biologic. A biosimilar must match enzyme activity, PEGylation, impurities, aggregation, and immunogenicity, not only the active protein sequence.
• Orphan exclusivity from the January 2018 approval would generally have reached its seven-year endpoint in January 2025, subject to any applicable pediatric extension.
• ASPARLAS should be analyzed under the biologics patent and exclusivity framework rather than through a conventional small-molecule Paragraph IV model.
• Formulation patents alone may not prevent competition, but manufacturing know-how and analytical complexity can create substantial practical barriers.
• The strongest licensing opportunities involve validated stability, delivery, container-closure, or pediatric-use improvements.

FAQs About ASPARLAS Excipient and Commercial Strategy

Can ASPARLAS be reformulated without changing its clinical dose?

Potentially, but the sponsor would need to demonstrate that the new formulation preserves potency, PEGylation, safety, immunogenicity, storage stability, dilution behavior, and administration compatibility.

Is polysorbate 80 essential to ASPARLAS?

It is part of the labeled formulation and likely reduces surface adsorption and aggregation. An alternative surfactant could be commercially attractive, but replacement would require comparative stability, particle, potency, and immunogenicity data.

Could a lyophilized ASPARLAS product reduce biosimilar risk?

A lyophilized presentation could create additional formulation and process protection, but it would not eliminate composition, process, or biologic comparability challenges for follow-on developers.

Does orphan exclusivity block an ASPARLAS biosimilar after 2025?

No. Orphan exclusivity is time-limited and separate from patent rights and biologic exclusivity. A biosimilar may still face patents, regulatory requirements, and BPCIA litigation after orphan exclusivity ends.

Which ASPARLAS formulation improvement has the highest commercial value?

A formulation that extends refrigerated shelf life while reducing vial wastage and maintaining the existing infusion process is likely to offer the best balance of clinical utility, regulatory feasibility, and hospital economics.

References

1. U.S. Food and Drug Administration. (2023). Asparlas (calaspargase pegol-mknl) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2018, January 22). FDA approves new treatment for acute lymphoblastic leukemia. FDA.

3. U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity. FDA.

4. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.

5. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §7002, 124 Stat. 119.